ADAM17: The new face of breast cancer-promoting metalloprotease activity

Cancer Biology and Therapy

Volumn 8, Issue 11, 2009, Pages 1055-1057

  Glunde, Kristine ^a   Stasinopoulos, Ioannis ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADAM17; Breast cancer; Breast development; Ectodomain shedding; EGF signaling; Inflammation; TNF ; Tumor microenvironment

Indexed keywords

AMPHIREGULIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METALLOPROTEINASE; NEU DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 5;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; ENZYME ACTIVITY; HUMAN; INFLAMMATION; NOTE; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADAM PROTEINS; BREAST NEOPLASMS; FEMALE; HUMANS; METALLOPROTEASES;

EID: 68049117191     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.11.8758     Document Type: Note

References (17)

1. Sternlicht MD, Kouros-Mehr H, Lu P, Werb Z. Hormonal and local control of mammary branching morphogenesis. Differentiation 2006; 74:365-81.
2. Sternlicht MD, Sunnarborg SW. The ADAM17-amphiregulin-EGFR axis in mammary development and cancer. J Mammary Gland Biol Neoplasia 2008; 13:181-94.
3. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2008; 29:258-89.
4. Bax DV, Messent AJ, Tart J, van Hoang M, Kott J, Maciewicz RA, et al. Integrin alpha-5beta1 and ADAM-17 interact in vitro and co-localize in migrating HeLa cells. J Biol Chem 2004; 279:22377-86.
5. Huang J, Bridges LC, White JM. Selective modulation of integrin-mediated cell migration by distinct ADAM family members. Mol Biol Cell 2005; 16:4982-91.
6. Tellier E, Canault M, Rebsomen L, Bonardo B, Juhan-Vague I, Nalbone G, et al. The shedding activity of ADAM17 is sequestered in lipid rafts. Exp Cell Res 2006; 312:3969-80.
7. Zhang Q, Thomas SM, Lui VW, Xi S, Siegfried JM, Fan H, et al. Phosphorylation of TNFalpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci USA 2006; 103:6901-6.
8. Wei S, Kashiwagi M, Kota S, Xie Z, Nagase H, Brew K. Reactive site mutations in tissue inhibitor of metalloproteinase-3 disrupt inhibition of matrix metalloproteinases but not tumor necrosis factor-alpha-converting enzyme. J Biol Chem 2005; 280:32877-82.
9. Zheng Y, Saftig P, Hartmann D, Blobel C. Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17). J Biol Chem 2004; 279:42898-906.
10. Duffy MJ, McKiernan E, O'Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. Clin Cancer Res 2009; 15:1140-4.
11. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008; 8:929-41.
12. McGowan PM, McKiernan E, Bolster F, Ryan BM, Hill AD, McDermott EW, et al. ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol 2008; 19:1075-81.
13. McGowan PM, Ryan BM, Hill AD, McDermott E, O'Higgins N, Duffy MJ. ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res 2007; 13:2335-43.
14. Kenny PA, Bissell MJ. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 2007; 117:337-45.
15. Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu Q, Chopp M. ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther 2009; 8:1057-9.
16. Zheng X, Jiang F, Katakowski M, Zhang X, Jiang H, Zhang ZG, et al. Sensitization of cerebral tissue in nude mice with photodynamic therapy induces ADAM17/TACE and promotes glioma cell invasion. Cancer Lett 2008; 265:177-87.
17. Rieger R, Whitacre D, Cantwell MJ, Prussak C, Kipps TJ. Chimeric form of tumor necrosis factor-alpha has enhanced surface expression and antitumor activity. Cancer Gene Ther 2009; 16:53-64.